Doctor profile · Federal record
Dr. Lindsay Dilbeck, P.A.
Physician Assistant · Tulsa, OK
- NPI 1730366550
- Accepts Medicare
- MIPS 88.0 / 100 · 2023
- 19 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
9940 E 81St St, Ste 100
Tulsa, OK 741334501
(918) 664-9881 - Mailing address
-
4152 E 48Th Pl
Tulsa, OK 741354739
Credentials & registration
- NPI registered
- January 2008 — 18 yrs on file
- Profile last updated
- October 27, 2009
- Year of graduation
- 2007 — 19 yrs since
- Specialty taxonomy
- 363A00000X — NUCC code
- State license (1)
- Oklahoma #1695
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1730366550. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
1,689
Distinct HCPCS
10
Medicare allowed
$118,076
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 510 | 106 | $5 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 324 | 253 | $72 | |
17000 |
Destruction of precancer skin growth, 1 growth | 198 | 150 | $38 | |
17110 |
Destruction of skin growth, 1-14 growths | 178 | 140 | $85 | |
11102 |
Biopsy of related skin growth, first growth | 111 | 93 | $66 | |
J7308 |
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 79 | 46 | $377 | |
96574 |
Application of light with debridement to destroy precancer skin growth | 67 | 44 | $214 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 62 | 55 | $103 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 49 | 47 | $45 | |
11103 |
Biopsy of related skin growth, each additional growth | 40 | 28 | $40 |
In context: peer comparison
Among 102 peers in Tulsa Physician Assistant, average services per provider: 112. This provider delivers 15× the peer median.Open Payments
Industry payments received
All-time total
$1,901
Transactions
93
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $480.07 | |
| Arcutis Biotherapeutics, INC. | 15 | $223.70 | |
| Sun Pharmaceutical Industries INC. | 11 | $205.17 | |
| Abbvie INC. | 11 | $189.18 | |
| Novartis Pharmaceuticals Corporation | 7 | $140.92 | |
| Janssen Biotech, INC. | 5 | $136.44 | |
| Amgen INC. | 5 | $129.66 | |
| Lilly USA, LLC | 5 | $77.40 | |
| Dermavant Sciences, INC. | 4 | $72.75 | |
| Leo Pharma INC. | 3 | $69.62 | |
| Ucb, INC. | 4 | $68.56 | |
| Mayne Pharma Commercial LLC | 3 | $34.12 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | 2 | $26.81 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | 1 | $20.13 | |
| Genzyme Corporation | 1 | $13.43 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
173
Patients
94
Total drug cost
$104,983
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Mupirocin | Generic | 28 | 28 | $331 |
| Doxycycline Hyclate | Generic | 26 | 16 | $806 |
| Fluocinonide | Generic | 26 | 19 | $1,649 |
| Otezla (Apremilast) | Brand | 21 | 0 | $99,792 |
| Ketoconazole | Generic | 20 | 0 | $628 |
| Triamcinolone Acetonide | Generic | 20 | 17 | $218 |
| Clobetasol Propionate | Generic | 18 | 14 | $1,226 |
| Ciclopirox (Ciclopirox Olamine) | Brand | 14 | 0 | $333 |
Frequently asked questions
What is Dr. Lindsay Dilbeck's medical specialty?
Dr. Lindsay Dilbeck practices Physician Assistant in Tulsa, OK.
Where does Dr. Lindsay Dilbeck practice?
Dr. Lindsay Dilbeck practices at 9940 E 81St St, Tulsa, OK 741334501. Office phone: 9186649881.
What is Dr. Lindsay Dilbeck's NPI?
Dr. Lindsay Dilbeck's National Provider Identifier (NPI) is 1730366550, issued by NPPES.
Does Dr. Lindsay Dilbeck accept Medicare assignment?
Yes. Dr. Lindsay Dilbeck accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Lindsay Dilbeck commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213); Destruction of precancer skin growth, 1 growth (HCPCS 17000). Source: CMS Medicare Physician & Other Practitioners file.